The patent for semaglutide, the compound behind drugs such as Wegovy and Ozempic, developed by Novo Nordisk, is set to expire in India on Friday, potentially opening the door to cheaper generic versions, the BBC reported.
The change is expected to allow domestic pharmaceutical companies to produce lower-cost alternatives, increasing competition and driving prices down. Analysts say dozens of branded generics could enter the market within months, reflecting India’s highly competitive generics industry. Investment bank Jefferies has described the development as a potential turning point, estimating the Indian semaglutide market could reach $1 billion with wider adoption, even...